Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development
Aileron Therapeutics Inc
Circle Pharma Inc
Dicer Pharmaceuticals Inc
Fog Pharmaceuticals Inc
iBeCa Therapeutics
MD2 Biosciences Inc
PRISM Pharma Co Ltd
Propanc Biopharma Inc
Sapience Therapeutics Inc
Stemsynergy Therapeutics Inc
Sumitomo Dainippon Pharma Oncology, Inc
Venn Therapeutics LLC
WntRx Pharmaceuticals Inc
Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles
Antisense Ri Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBI-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exisulind - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nefopam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides for Hepatoblastoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRI-724 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Beta Catenin and BCL9 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Beta Catenin for Colorectal Cancer and Brain Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta Catenin for Unspecified Cancers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta Catenin for Unspecified Cancers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CTNNB1 for Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit CTNNB1 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WX-024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products
Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones
Featured News & Press Releases
Dec 21, 2020: Propanc Biopharma receives first granted patent for method to treat cancer stem cells from Australian Patent Office
Jun 17, 2020: Sapience Therapeutics to present data on ?-catenin antagonist program at 2020 AACR Virtual Annual Meeting II
Apr 14, 2020: Propanc Biopharma receives first allowance for key patent family from Australian Patent Office
Jan 21, 2020: Propanc Biopharma receives advance overseas finding from Innovation and Science Australia
Oct 21, 2019: Propanc Biopharma illustrates novel mode of action of PRP, suppressing EMT Pathways and Metastasis in Cancer Patients
Aug 21, 2019: Propanc Biopharma receives granted US patent covering additiol composition claims for PRP
Aug 12, 2019: Propanc Biopharma publishes key data in peer reviewed jourl confirming anti-cancer stem cell effects of Proenzymes
Aug 08, 2019: Propanc Biopharma completes development of bio-alytical assay method to quantify PRP active ingredients in preparation for first-in-human study
Jul 15, 2019: Propanc Biopharma provides update on preparation of PRP for clinical trial application submission and recently completed reverse stock split
Jun 27, 2019: Propanc Biopharmas Intellectual Property portfolio undergoes rapid growth
May 06, 2019: Propanc Biopharma appoints Dr. Ralf Brandt to its scientific advisory board
Apr 26, 2019: Announcement of the signing of a joint R & D agreement and commencement of development activities regarding “Research and development of innovative antifibrotic drugs to improve the life prognosis of cirrhosis”
Mar 25, 2019: Propanc Biopharma initiates development of bio-alytical assay in preparation for human trials
Mar 13, 2019: Propanc Biopharma receives notice of allowance for additiol claims from foundation patent in the U.S.
Dec 20, 2018: Novel development drug OP-724 (PRI-724) for the treatment of cirrhosis is published on ture Outline
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Aileron Therapeutics Inc, 2021
Pipeline by Circle Pharma Inc, 2021
Pipeline by Dicerna Pharmaceuticals Inc, 2021
Pipeline by Fog Pharmaceuticals Inc, 2021
Pipeline by iBeCa Therapeutics, 2021
Pipeline by MD2 Biosciences Inc, 2021
Pipeline by PRISM Pharma Co Ltd, 2021
Pipeline by Propanc Biopharma Inc, 2021
Pipeline by Sapience Therapeutics Inc, 2021
Pipeline by Stemsynergy Therapeutics Inc, 2021
Pipeline by Sumitomo Dainippon Pharma Oncology, Inc, 2021
Pipeline by Venn Therapeutics LLC, 2021
Pipeline by WntRx Pharmaceuticals Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)